hotgen
Company Profile
Beijing Hotgen Biotech Co., Ltd. (hereinafter referred to as “Hotgen Biotech”) was founded in 2005. It is a high-tech enterprise focusing on the biopharmaceutical field and was listed on the STAR Market of the Shanghai Stock Exchange in September 2019 (Stock Code: 688068). The Institute of Future Technology, our innovation incubation platform, is dedicated to transforming advanced scientific discoveries into products. Its focus areas include nucleic acid drugs, antibody drugs, and biotechnology health and beauty consumer products. Among its breakthroughs, the world’s first antibody drug for myocardial infarction emergency treatment has obtained dual IND approvals in China and the United States, as well as FDA Fast Track designation.
